You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
|
|---|---|
| Published in |
Orphanet Journal of Rare Diseases, September 2018
|
| DOI | 10.1186/s13023-018-0916-1 |
| Pubmed ID | |
| Authors |
Malte Lenders, Boris Schmitz, Stefan-Martin Brand, Eva Brand |
| Abstract |
Fabry disease (FD) is a rare X-linked disorder caused by a deficiency of lysosomal α-galactosidase A activity. Treatment with recombinant enzyme replacement therapy is available since 2001 and the effects of anti-drug antibodies (ADA) on therapy efficacy and disease outcome in affected patients have been controversially reported. In this letter we discuss the importance of adequate measurements of neutralizing ADAs and appropriate longitudinal analysis to determine therapy efficiency and clinical outcome in patients with FD. |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 33% |
| Student > Bachelor | 2 | 13% |
| Student > Doctoral Student | 2 | 13% |
| Student > Master | 2 | 13% |
| Student > Ph. D. Student | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 3 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 33% |
| Agricultural and Biological Sciences | 3 | 20% |
| Nursing and Health Professions | 1 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 3 | 20% |